May 26, 2008
TRANS GENI INC.

   

Notice of Conclusion of Marketing Agreement with ProteinTech Group, Inc.


We hereby announce that TransGenic Inc. (hereinafter referred to as q�weq� or q㎡sq�) has concluded as of May 26 ,2008 a marketing agreement with ProteinTech Group, Inc., headquartered in Chicago, Illinois, U.S.A., (hereinafterreferred to as q⑰roteinTechq�), for the exclusive rights to market ProteinTechq�s products in Japan.

ProteinTech develops, produces and distributes antibody products and provides custom production services of antibodies. Their product lineup covers more than 2,000 kinds of self-developed antibody reagents and over 1,000 kinds of life-science related products such as recombinant proteins. ProteinTech has already enjoyed excellent sales performance not only in Europe and the U.S. but also in Japan due to the following assets of their development strategies and products.

1)

 

Their main strategy is to set target antibodies which remain underdeveloped and focus on cyclopaedically developing them to produce and release new products ahead of other competitors in the market, so that the products are likely to become standards

2)

To realize the strategy, they have established an efficient system to commercialize a large number of products in a short period of time. Actually, they have released over 2,000 kinds of new antibody products for the last two years.

3)

They have sophisticated technologies not only for antibody development but for quality evaluation.
Therefore they can provide high-quality products whose usefulness and conditions of use have been
confirmed.

Utilizing know-how that we have accumulated through developing and distributing antibody products, we intend to disseminate competitiveness of ProteinTechq�s products across the market and offer technological support to various laboratories. ProteinTechq�s products will be delivered to laboratories anywhere in Japan in a short time, since we will have a repository of their products in our Kobe Research Center.

The tie-up with ProteinTech this time is a first step for a technological and business partnership planned in the future. We will further enhance cooperation with them to provide even better products and services.

With the help of Life Sciences Business Unit, Advanced Sciences & Technologies Division of Mitsubishi
Corporation, we have brought technologies, products and services of foreign bio-tech companies to the Japanese market, such as Deltagen, Inc. (California, U.S.A., President and CEO: Robert J. Driscoll, J.D.) and TriStar Technology Group, LLC. (Maryland, U.S.A., President: Milan Bhagat). The marketing agreement with
ProteinTech is a part of these efforts. We will continuously introduce new technologies useful for researches in the field of life sciences.

The impact this marketing agreement will have on our business performance has been closely examined, and we intend to make an announcement in the future when it starts to have a significant impact on our business performance.


Overview of ProteinTech Group, Inc.
Established:
2002
Corporate Headquarters:
 Chicago, Illinois, U.S.A.
Chairman of the Board and CEO:
 Jianxun Li
Main Products and Services:
 Antibody products and custom production services of antibodies
URL:
http://www.ptglab.com/
 
 
 
PRINT
BACK